Drug resistance reversing effect of Chinese herb monomer  plumbagin on baumanii

Abstract

Abstract: AIM: To explore the drug resistance reversing effect of Chinese herb simple substance plumbagin on baumanii. METHODS: Fifty-three strains of baumanii were isolated from patients. The antibacterial activities of 14 kinds of antibacterial drugs commonly used in clinic were detected. The direct antibacterial activities of Chinese herb monomer of plumbagin on standard strains were studied. After the determination of plumbagin and carbonyl cyanide m-chlorophenylhydrazone(CCCP) work concentration, the efflux inhibition test results of plumbagin and CCCP were compared.RESULTS: The resistance rate of 53 clinical isolates of baumanii to 14 kinds of clinical commonly used antimicrobial drugs was high.The ampicillin,cefazolin, cefuroxime, cefoxitin resistance rate was highest,respectively 100%,100%,98.1% and 98.1%. The rest of the drug-resistant rate is above 50%.The direct antimicrobial effect of plumbagin on quality standard bacteria was weak. Plumbagin and CCCP showed increasing sensitization to gentamicin, norfloxacin, minocycline hydrochloride and chloramphenicol. Their positive rates of efflux were 11.3% and 18.9%, 3.8% and 7.5%, 13.2% and 20.8%, 28.3% and 20.8%, respectively. There were no statistical differences between two groups.CONCLUSION: The clinical drug resistance of baumanii is in serious condition, and plumbagin as a kind of traditional Chinese medicine monomer may have a certain role in the drug resistance reversal.

Key words: plumbagin, CCCP, baumanii, drug resistance

CLC Number:

R965.2

LI Juan, LI Xiao-ning, ZHONG Zheng-ling, CHU Ji-ru, YU Wen-tao, ZHANG Xue-feng, XIE Hai-tang. Drug resistance reversing effect of Chinese herb monomer plumbagin on baumanii[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 155-159.

References

[1] Peleg AY,Seifert H,Paterson DL.Acinetobacter baumannii:emergence of asuccessful pathogen[J].Clin Microbiol Rev, 2008,21(3):538-582.
[2] Livermore DM.Has the eraofuntreatable infections arrived[J]?J Antimicrob Chemother,2009,64(Suppl1):i29-36.
[3] Tao C,Kang M,Chen Z,et al. Microbiologic study of the pathogens isolated from woundculture among Wenchuan earthquake survivors[J].Diagn Microbiol Infect DIS,2009,63(3):268-270.
[4] Pagès JM, Amaral L, Fanning S. An original deal for new molecule: reversal of efflux pump activity, a rational strategy to combat gram-negative resistant bacteria[J]. Curr Med Chem, 2011,18(19):2969-2980.
[5] Pagès JM, Amaral L. Mechanisms of drug efflux and strategies to combat them: Challenging the efflux pump of Gram-negative bacteria[J]. Biochim Biophys Acta, 2009, 1794(5):826-833.
[6] Pagès JM, Sandrine AF, Mahamoud A, et al.Efflux pumps of gram-negative bacteria, a new target for new molecules[J]. Curr Top Med Chem, 2010, 10(18):1848-1857.
[7] Padhye S, Dandawate P, Yusufi M, et al. Perspectives on medicinal properties of plumbagin and its analogs[J]. Med Res Rev, 2012, 32(6):1131-1158.
[8] Koh KH, Tham FY.Screening of traditional Chinese medicinal plants for quorum-sensing inhibitors activity[J]. J Microbiol Immunol Infect, 2011,44(2):144-148.
[9] Padhye S, Dandawate P, Yusufi M, et al. Perspectives on medicinal properties of plumbagin and its analogs[J]. Med Res Rev, 2012 ,32(6):1131-1158.
[10]周云.多种外排泵抑制剂逆转鲍曼不动杆菌耐药性的研究[D].川北医学院,2011.
[11]凌保东. 鲍曼不动杆菌抗生素多重耐药性:耐药机制与感染治疗对策[J].中国抗生素杂志, 2010,35(4) :241-254.
[12]李小宁,李娟,姚永红. 鲍曼不动杆菌的耐药性及产ESBL和碳青霉烯酶分析[J].中国临床药理学与治疗学,2012,17(1):30-33.
[13]Fernandez-Cuenca F,Martinez-Martinez L,Conejo MC,et a1.Relationship between β-lactamase production,outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii[J].J Antimicrob Chemother,2003,51(3):565-574.
[14]Jacoby GA.Mechanisms of resistance to quinolones[J].Clin Infect Dis,2005,41 (Suppl 2):S120-126.
[15]Yamane K,Wachino J,Doi Y,et al.Global spread of multiple aminoglycoside resistance genes[J].Emerg Infect Dis,2005,11(6):951-953.
[16]Nikaido H.Molecular basis of bacterial outer membrane permeability revisited[J].Microbiol Mol Biol Rev, 2003,67(4):593-656.
[17]McMurray LM, Petrucci RE, Levy SB. Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli[J]. Proc Natl Acad Sci USA,1980,77(7):3974.
[18]Lin L,Ling BD,Li XZ.Distribution of the multidrug efflux pump genes,adeABC,adeDE and adelJK,and class 1 integron genes in multiple-anfimicrobial-resistant clinical isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex[J].Int J Antimicrob Agents,2009,33(1):27-32.
[19]何玉明.中药对细菌耐药性干预的研究进展[C]. 第二届临床中药学学术研讨会论文集,2009.
[20]霍仕霞,闫明. 白花丹的研究进展[J].中国医药导报,2008,5(28):17-18.

Drug resistance reversing effect of Chinese herb monomer plumbagin on baumanii

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[2]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[3]	DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli. Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
[4]	MENG Qiang, LIU Kexin. Research status and prospect of transporter-mediated drug-drug interactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 876-888.
[5]	YANG Hechun, SHI Daohua . Research progress of small molecule inhibitors that reverse tumor drug resistance by regulating tumor glucose metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 836-840.
[6]	WEI Songchang, YANG Hongqi, ZHANG Hongjuan, SHI Xiaoli, REN Kaiwen. Correlation between the expression of RON protein and CXC chemokine receptor 4 protein and abiraterone resistance in patients with castration-resistant prostate cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 414-422.
[7]	JIN Le, JIANG Duochen, CHEN Hongxiao, LIU Su, CHEN Zhaolin, JU Jing. Quercetin reverses adriamycin resistance by activating GSK-3β/β-catenin pathways through GAS5 in breast cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1344-1351.
[8]	YUAN Xing, SU Yan, XU Zhenguo, LI Zisheng. Study on drug-resistant phonotype and plasmid-mediated quinolone resistance genes in Acinetobacter baumannii isolates [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1111-1117.
[9]	WANG Ziyuan, SUN Mingyu. Advances in research on long non-coding RNA in drug resistance of colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 796-802.
[10]	YANG Yanlang, LI Yan, WANG Lin. Distribution and drug resistance of bacterial pathogens in the infecting inpatients of department of nephrology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 203-208.
[11]	XU Weiping, ZHOU Weiying. Advances in the sensitization mechanism of chemotherapeutic drugs for bladder cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1060-1064.
[12]	WANG Xiaoli, LU Shuping, DAI Jiale. Role of MSX2 in melanoma cells for trametinib resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1147-1154.
[13]	FU Peishu, SUN Fengjun, FENG Wei, XIONG Lirong, LI Xiaoyu, XIA Peiyuan. Progress in drug therapy for multidrug-resistant Acinetobacter baumannii infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1181-1187.
[14]	LI Zhaoxia，WANG Rui，LI Aimin，LIU Youning. Study of the primary target and mutation position in nemonoxacin-resistant mutants of Staphlococcus aureus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 667-671.
[15]	YE Haizhu, CHEN Yajuan, ZHAO Wenying, LIU Xiaoping. Different expression of FoxO3/Keap1/Nrf2 pathway in tumor cells and drug resistant tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 859-865.